LXRX Lexicon Pharmaceuticals Inc.

3.36
-0.09  -2%
Previous Close 3.44
Open 3.49
Price To Book 2.17
Market Cap 357,073,675
Shares 106,271,927
Volume 1,296,419
Short Ratio
Av. Daily Volume 1,487,942
Stock charts supplied by TradingView

NewsSee all news

  1. Lexicon Pharmaceuticals Announces Real-World Data on Telotristat Ethyl's Antiproliferative Effects in Patients With Carcinoid Syndrome

    THE WOODLANDS, Texas, Jan. 24, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), announced today real-world data on XERMELO's® (telotristat ethyl) antiproliferative effects in patients with

  2. Lexicon Pharmaceuticals Announces Poster Presentation at the ASCO 2020 Gastrointestinal Cancers Symposium

    THE WOODLANDS, Texas, Jan. 20, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), announced today that data from a poster highlighting XERMELO® (telotristat ethyl) will be presented at the American

  3. Lexicon Pharmaceuticals to Present at Upcoming Investor Conference

    THE WOODLANDS, Texas, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that Lonnel Coats, President and Chief Executive Officer, will present at the following conference:

  4. Lexicon Pharmaceuticals Announces Topline Phase 3 Data for Sotagliflozin in Type 2 Diabetes

    THE WOODLANDS, Texas, Dec. 20, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), today announced topline data from the Phase 3 SOTA-EMPA study for sotagliflozin (Zynquista™) in type 2 diabetes. The

  5. Lexicon Pharmaceuticals Announces Positive Topline Phase 1 Data for LX9211

    THE WOODLANDS, Texas, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), today announced positive topline data from the Phase 1 multiple ascending dose study of LX9211, a potent oral small

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 data released September 9, 2016 met primary endpoint. Data from second trial released December 21, 2016 - primary endpoint met. Data from third trial also met primary endpoint - June 9, 2017.
Sotagliflozin
Type 1 Diabetes
Phase 2 trial did not meet primary endpoint.
Sotagliflozin
Type 1 Diabetes
CRL issued March 22, 2019. Appeal rejected by FDA - December 2, 2019.
Sotagliflozin
Type 1 Diabetes
Approved February 28, 2017.
Telotristat etiprate (XERMELO)
Carcinoid Syndrome
SNY informed LXRX July 26, 2019 that it plans to terminate its agreement following insufficient efficacy across three Phase 3 trials. Phase 3 data noted 400 mg achieved the primary endpoint of superiority - December 20, 2019. Further trial data due early-2020.
Sotagliflozin
Type 2 Diabetes
Phase 1 data December 5, 2019 noted drug was well tolerated. Proof of concept trial to be initiated 2020.
LX9211
Neuropathic pain
Phase 2a PFS data due 2020.
Telotristat ethyl - TELE-ABC
Biliary tract cancer (BTC)

Latest News

  1. Lexicon Pharmaceuticals Announces Real-World Data on Telotristat Ethyl's Antiproliferative Effects in Patients With Carcinoid Syndrome

    THE WOODLANDS, Texas, Jan. 24, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), announced today real-world data on XERMELO's® (telotristat ethyl) antiproliferative effects in patients with

  2. Lexicon Pharmaceuticals Announces Poster Presentation at the ASCO 2020 Gastrointestinal Cancers Symposium

    THE WOODLANDS, Texas, Jan. 20, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), announced today that data from a poster highlighting XERMELO® (telotristat ethyl) will be presented at the American

  3. Lexicon Pharmaceuticals to Present at Upcoming Investor Conference

    THE WOODLANDS, Texas, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that Lonnel Coats, President and Chief Executive Officer, will present at the following conference:

  4. Lexicon Pharmaceuticals Announces Topline Phase 3 Data for Sotagliflozin in Type 2 Diabetes

    THE WOODLANDS, Texas, Dec. 20, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), today announced topline data from the Phase 3 SOTA-EMPA study for sotagliflozin (Zynquista™) in type 2 diabetes. The

  5. Lexicon Pharmaceuticals Announces Positive Topline Phase 1 Data for LX9211

    THE WOODLANDS, Texas, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), today announced positive topline data from the Phase 1 multiple ascending dose study of LX9211, a potent oral small

  6. Lexicon Pharmaceuticals Completes Safety Review of Initial Safety Run-in Cohort of TELE-ABC Study, a Phase 2 Clinical Study of Telotristat Ethyl in Biliary Tract Cancer

    THE WOODLANDS, Texas, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), announced today the completion of a safety review of the initial run-in cohort of the Telotristat Ethyl for Advanced

  7. Lexicon Pharmaceuticals Receives Formal Dispute Resolution Request Decision From FDA's Office of New Drugs for Sotagliflozin in Type 1 Diabetes

    THE WOODLANDS, Texas, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), today announced that the Office of New Drugs of the U.S. Food and Drug Administration (FDA) has reiterated the

  8. Lexicon Pharmaceuticals to Present at Upcoming Investor Conference

    THE WOODLANDS, Texas, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that Jeffrey L. Wade, J.D., Executive Vice President, Corporate and Administrative Affairs and Chief

  9. Lexicon Pharmaceuticals to Present at Upcoming Investor Conference

    THE WOODLANDS, Texas, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that Lonnel Coats, President and Chief Executive Officer, will present at the following conference:

  10. Lexicon Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides a Business Update

    THE WOODLANDS, Texas, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), today reported financial results and provided a business update for the three months ended September 30, 2019. "We

  11. Lexicon Pharmaceuticals to Host Third Quarter 2019 Financial Results Conference Call and Webcast on November 7, 2019

    THE WOODLANDS, Texas, Oct. 31, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), will release its third quarter 2019 financial results on Thursday, November 7, 2019 before market opens. Management

  12. Lexicon Pharmaceuticals Announces Poster Presentations at the NANETS Annual Multidisciplinary NET Medical Symposium

    THE WOODLANDS, Texas, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), announced today that data from five posters highlighting XERMELO® (telotristat ethyl) will be presented at the

  13. Lexicon Pharmaceuticals Announces Termination of Alliance and Settlement With Sanofi

    THE WOODLANDS, Texas, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), today announced the termination of its alliance with Sanofi for the development and commercialization of ZynquistaTM

  14. Lexicon Pharmaceuticals to Present Sotagliflozin Clinical Data at the European Association for the Study of Diabetes 55th Annual Meeting

    THE WOODLANDS, Texas, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), today announced that clinical data for ZynquistaTM (sotagliflozin) will be presented at the upcoming European

  15. Lexicon Pharmaceuticals To Present At Upcoming Investor Conference

    THE WOODLANDS, Texas, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that Jeffrey L. Wade, J.D., Executive Vice President, Corporate and Administrative Affairs and Chief